VLA-4 Agonists – Enhancing Hematopoietic Stem Cell Engraftment, Accelerating Immune Reconstitution, and Increasing Treatment Success Rates for Patient

VLA-4 Agonists – Enhancing Hematopoietic Stem Cell Engraftment, Accelerating Immune Reconstitution, and Increasing Treatment Success Rates for Patient

Hematopoietic stem cell transplantation (HSCT) is an effective, and often the only, curative treatment for malignant hematological diseases such as leukemia. Key steps that impact the success of the transplantation include stem cell engraftment and the reconstitution of immune functions. From April 14 to 17, 2024, the 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting was grandly held in Glasgow, UK. The conference focused on the latest advancements in stem cell transplantation and cell therapy, driving better clinical outcomes for patients with hematological diseases. At this conference, a team led by Professor Xianmin Song from Shanghai First People's Hospital presented an oral report titled "VLA-4 Agonists Promote Engraftment and Cellular Immune Reconstitution in Allogeneic Hematopoietic Stem Cell Transplantation," which garnered widespread attention. Professor Song was specially invited to our live interview room to share the main findings of his research and provide a detailed explanation of the latest developments in the critical steps of allogeneic stem cell transplantation: graft engraftment and immune reconstitution.
EBMT 2024 | Professor Qingxiao Song: PI3Kδ Inhibitors Show High Potential in the Treatment of cGVHD

EBMT 2024 | Professor Qingxiao Song: PI3Kδ Inhibitors Show High Potential in the Treatment of cGVHD

Chronic graft-versus-host disease (cGVHD) is a clinical syndrome occurring after allogeneic hematopoietic stem cell transplantation (allo-HSCT), where the recipient’s organs are attacked by donor-derived lymphocytes during the reconstitution of the donor's immune system. This includes both classic cGVHD and overlapping syndromes and is one of the main complications of transplantation, with an incidence rate of 30% to 70%. The mechanisms behind cGVHD are complex, its clinical manifestations diverse, and the individual differences significant. The course of the disease can be prolonged and persistent; if not properly diagnosed and treated, it can severely affect the patient's quality of life and long-term survival. With the introduction of guidelines, there are now standardized diagnostic criteria and first-line treatment protocols for cGVHD, but there is still no consensus on second-line treatments. PI3Kδ inhibitors, which interfere with the proliferation and survival of lymphocytes by inhibiting the activity of the PI3Kδ enzyme and thus suppress tumor growth, have not only introduced new drugs and strategies for non-Hodgkin's lymphoma but have also shown therapeutic potential in the treatment of GVHD. At the recent 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting, a basic study from the Second Affiliated Hospital of Army Medical University was selected for an oral presentation (Abstract No: OS7-05) [1], showcasing the activity of PI3Kδ inhibitors in the treatment of cGVHD. "Oncology Frontier - Hematology Frontier" has invited Professor Qingxiao Song from The Second Affiliated Hospital of Army Medical University (Xinqiao Hospital) to interpret and comment on this research for our readers.there is still no consensus on second-line treatments. PI3Kδ inhibitors, which interfere with the proliferation and survival of lymphocytes by inhibiting the activity of the PI3Kδ enzyme and thus suppress tumor growth, have not only introduced new drugs and strategies for non-Hodgkin's lymphoma but have also shown therapeutic potential in the treatment of GVHD. At the recent 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting, a basic study from the Second Affiliated Hospital of Army Medical University was selected for an oral presentation (Abstract No: OS7-05) [1], showcasing the activity of PI3Kδ inhibitors in the treatment of cGVHD. "Oncology Frontier - Hematology Frontier" has invited Professor Qingxiao Song from The Second Affiliated Hospital of Army Medical University (Xinqiao Hospital) to interpret and comment on this research for our readers.
Professor Pizzi Interprets the 2023 ESC Endocarditis Guidelines Update at ESCMID Global 2024

Professor Pizzi Interprets the 2023 ESC Endocarditis Guidelines Update at ESCMID Global 2024

Infective Endocarditis (IE) is a serious infectious cardiac condition. With advancements in medical technology, there have been significant changes in the diagnosis and treatment paradigms for IE. At the 34th European Congress of Clinical Microbiology & Infectious Diseases (ESCMID Global 2024), Infection Medicine Online had the privilege of interviewing Professor Maria Nazarena Pizzi from Vall d'Hebron University Hospital in Barcelona. Not only is Professor Pizzi a distinguished cardiologist, but she also participated in the update of the European Society of Cardiology (ESC) guidelines on endocarditis. In this interview, Professor Pizzi shared her expert insights on the updates to the 2023 ESC endocarditis guidelines, the application of imaging technologies, and the value of molecular diagnostic techniques
Definition and Diagnostic Criteria for Acute-on-Chronic Liver Failure: An Eastern Perspective

Definition and Diagnostic Criteria for Acute-on-Chronic Liver Failure: An Eastern Perspective

The "Acute-on-Chronic Liver Failure (ACLF) Monthly Review" is a scholarly column produced by the Chinese Acute-on-Chronic Liver Failure Consortium at the invitation of the editorial department of the journal Liver International. Each month, the column focuses on a specific area of ACLF to disseminate knowledge about the concept and significance of ACLF and to help readers stay updated on recent developments in the field. The aim is to benefit both liver disease specialists and researchers interested in field hotspots, as well as frontline clinical practitioners in need of practical knowledge.
 EBMT 2024 | Professor Linhua Yang: Embracing the Pulse of the Era, Focusing on the Advancements of Allogeneic Hematopoietic Stem Cell Transplantation and Cellular Immunotherapy in Hematologic Malignancies

 EBMT 2024 | Professor Linhua Yang: Embracing the Pulse of the Era, Focusing on the Advancements of Allogeneic Hematopoietic Stem Cell Transplantation and Cellular Immunotherapy in Hematologic Malignancies

From April 14 to 17, 2024, the 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting was grandly held in Glasgow, UK. The conference focused on the latest advancements in stem cell transplantation and cellular therapy, pushing forward better clinical outcomes for patients with blood diseases and hematologic malignancies. In this issue, we are honored to have Professor Linhua Yang share selected advancements in the fields of allogeneic hematopoietic stem cell transplantation and cellular immunotherapy. We welcome our readers to engage and share their insights.
2023 COMB | Professor Fei Ma: The Knowns and Unknowns of Breast Cancer Immunotherapy

2023 COMB | Professor Fei Ma: The Knowns and Unknowns of Breast Cancer Immunotherapy

The 6th Precision Oncology Summit and the 9th Individualized Breast Cancer Treatment Conference (2023 COMB) took place from December 23 to 26, 2023, combining both online and offline formats. During the event, Professor Fei Ma from the Cancer Hospital of the Chinese Academy of Medical Sciences delivered an insightful presentation titled "The Knowns and Unknowns of Breast Cancer Immunotherapy." Following his presentation, Oncology Frontier conducted an exclusive interview with Professor Ma to discuss the latest advancements in breast cancer immunotherapy.
Professor Qiang Liu: Progress in the Treatment of Early Triple-Negative Breast Cancer | Annual Review of the Northern Breast Cancer Salon

Professor Qiang Liu: Progress in the Treatment of Early Triple-Negative Breast Cancer | Annual Review of the Northern Breast Cancer Salon

From January 5-6, 2024, the "Northern Breast Cancer Salon Annual Review and 2024 CSCO BC Guidelines Update Discussion" was held in Beijing. During the session on "Targeted Treatment-TNBC," Professor Qiang Liu from Sun Yat-sen Memorial Hospital of Sun Yat-sen University presented a report on "Progress in the Treatment of Early Triple-Negative Breast Cancer (TNBC)." After the session, "Oncology Frontier" conducted an exclusive interview with Professor Liu on the treatment of patients with early TNBC. The detailed content is organized below.
Professor Ming Liu on the Advances in Bipolar Androgen Therapy for mCRPC

Professor Ming Liu on the Advances in Bipolar Androgen Therapy for mCRPC

Bipolar Androgen Therapy (BAT) is an emerging treatment for metastatic castration-resistant prostate cancer (mCRPC) that significantly reduces prostate-specific antigen (PSA) levels in some patients, improves their quality of life, and restores sensitivity to castration treatments. This therapy has shown great potential in the treatment of mCRPC patients. On January 6, 2024, the "2024 Beijing Urological Tumors Youth Forum," co-hosted by the Beijing Cancer Fighting Association’s Young Committee for Urological Malignancies and the Beijing Medical Award Foundation, was successfully held in Beijing. Professor Ming Liu, Head of Urology at Beijing Hospital, delivered an insightful presentation titled "Early Experiences with Sequential Bipolar Androgen Therapy Combined with PD-1 Treatment in mCRPC," and discussed the concept and progress of BAT in an interview with "Oncology Frontier."